Synergistic induction of folate receptor β by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5875-5882

  Qi, Huiling ^a   Ratnam, Manohar ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDEAZATETRAHYDROFOLATE; FOLATE RECEPTOR; FOLATE RECEPTOR BETA; FOLIC ACID ANTAGONIST; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; REPRESSOR PROTEIN; REPRESSOR PROTEIN AP1; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SPECIFICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER PROTEINS; CHO CELLS; CRICETINAE; DRUG SYNERGISM; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOCYTIC, ACUTE; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATES; TRANSCRIPTION FACTOR AP-1; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VALPROIC ACID;

EID: 33745280074     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4048     Document Type: Article

References (31)

1. Bishop JF. Adult acute myeloid leukaemia: update on treatment. Med J Aust 1999;170:39-43.
2. List A. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996;10:937-42.
3. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
4. Tallman MS, Andersen JW, Schiffer CA, et al. AR-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8.
5. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002;100:594-602.
6. Ratnam M, Hao H, Zheng X, et al. Receptor induction and targeted drug delivery: a new antileukaemia strategy. Expert Opin Biol Ther 2003;3:563-74.
7. Wang H, Zheng X, Behm FG, Ratnam M. Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. Blood 2000;96:3529-36.
8. Hao H, Qi H, Ratnam M. Modulation of the folate receptor type β gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and represser AP-1 sites. Blood 2003;101:4551-60.
9. Kamen BA, Smith AK. A review of folate receptor α cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 2004;56:1085-97.
10. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002;54:675-93.
11. Theti DS, Bavetsias V, Skelton LA, et al. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the α-isoform of the folate receptor. Cancer Res 2003;63:3612-8.
12. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-84.
13. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44-51.
14. Jackman AL, Theti DS, Gibbs DD. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 2004;56:111-25.
15. Leamon CP, Reddy JA, Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127-41.
16. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004;56:1177-92.
17. Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56:1161-76.
18. Roy EJ, Gawlick U, Orr BA, Kranz DM. Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev 2004;56:1219-31.
19. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004;56:1193-204.
20. Ratnam M, Marquardt H, Duhring JL, Freisheim JH. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 1989;28:8249-54.
21. Ross JF, Wang H, Behm FG, et al. Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999;85:348-57.
22. Nakashima-Matsushita N, Homma T, Yu S, et al. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1609-16.
23. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the β-isoform of the folate receptor on CD34(+) cells. Blood 1999;93:3940-8.
24. Wu M, Fan J, Gunning W, Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J Membr Biol 1997;159:137-47.
25. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
26. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 1992;44:1898-901.
27. Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989;49:4435-40.
28. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S. Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 1999;93:4264-76.
29. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S. Transactivation via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif. Mol Endocrinol 2001;15:1677-92.
30. Smale ST, Kadonaga JT. The RNA polymerase II core promoter. Annu Rev Biochem 2003;72:449-79.
31. Schulman IG, Chakravarti D, Juguilon H, Romo A, Evans RM. Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation. Proc Natl Acad Sci U S A 1995;92:8288-92.